U.S. markets close in 3 hours 18 minutes
  • S&P 500

    4,461.62
    -19.08 (-0.43%)
     
  • Dow 30

    34,691.50
    -122.89 (-0.35%)
     
  • Nasdaq

    15,108.23
    -53.30 (-0.35%)
     
  • Russell 2000

    2,228.04
    -6.41 (-0.29%)
     
  • Crude Oil

    72.37
    -0.24 (-0.33%)
     
  • Gold

    1,754.90
    -39.90 (-2.22%)
     
  • Silver

    22.76
    -1.04 (-4.35%)
     
  • EUR/USD

    1.1766
    -0.0060 (-0.51%)
     
  • 10-Yr Bond

    1.3340
    +0.0300 (+2.30%)
     
  • GBP/USD

    1.3786
    -0.0049 (-0.36%)
     
  • USD/JPY

    109.7010
    +0.3410 (+0.31%)
     
  • BTC-USD

    48,064.59
    -166.11 (-0.34%)
     
  • CMC Crypto 200

    1,235.15
    +1.86 (+0.15%)
     
  • FTSE 100

    7,027.48
    +10.99 (+0.16%)
     
  • Nikkei 225

    30,323.34
    -188.37 (-0.62%)
     

4D pharma to Participate in Ladenburg Thalmann Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

LEEDS, England, June 29, 2021--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces that Duncan Peyton, Chief Executive Officer, and Alex Stevenson, Chief Scientific Officer, will present a corporate overview followed by a fireside chat at the virtual Ladenburg Thalmann Healthcare Conference on Tuesday, July 13, 2021, at 2:30pm ET (7:30pm BST).

A webcast of the presentation will be available via the ‘Events’ section of the 4D pharma website at www.4dpharmaplc.com. An archived replay of the webcast will be available for 90 days following the presentation.

About 4D pharma

4D pharma is a world leader in the development of Live Biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacterium, that is applicable to the prevention, treatment or cure of a disease. 4D has developed a proprietary platform, MicroRx®, that rationally identifies Live Biotherapeutics based on a deep understanding of function and mechanism.

4D pharma's Live Biotherapeutic products (LBPs) are orally delivered single strains of bacteria that are naturally found in the healthy human gut. The Company has five clinical programs, namely a Phase I/II study of MRx0518 in combination with KEYTRUDA (pembrolizumab) in solid tumors, a Phase I study of MRx0518 in a neoadjuvant setting for patients with solid tumors, a Phase I study of MRx0518 in patients with pancreatic cancer, a Phase I/II study of MRx-4DP0004 in asthma, and Blautix® in Irritable Bowel Syndrome (IBS) which has completed a successful Phase II trial. Preclinical-stage programs include candidates for CNS disease such as Parkinson's disease and other neurodegenerative conditions. The Company has a research collaboration with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ, USA, to discover and develop Live Biotherapeutics for vaccines.

For more information, refer to https://www.4dpharmaplc.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20210629005157/en/

Contacts

4D pharma
Investor Relations: ir@4dpharmaplc.com

N+1 Singer - Nominated Adviser and Joint Broker +44 (0)20 7496 3000
Philip Davies / Iqra Amin / James Fischer (Corporate Finance)
Tom Salvesen (Corporate Broking)

Bryan Garnier & Co. Limited - Joint Broker +44 (0)20 7332 2500
Dominic Wilson / Phil Walker

Stern Investor Relations, Inc. +1-212-362-1200
Julie Seidel Julie.seidel@sternir.com

Image Box Communications +44 (0)20 8943 4685
Neil Hunter / Michelle Boxall
neil@ibcomms.agency / michelle@ibcomms.agency